LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating Ionis Pharmaceuticals Inc. (“Ionis” or the “Company”) (Nasdaq: IONS) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Ionis shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
Ionis’s subsidiary Akcea Therapeutics released data from a Phase 3 study of volanesorsen, a treatment for familial chylomicronemia syndrome.
Akcea disclosed that 10 of the 66 patients that were involved in the study have discontinued treatment, many alleging injection site reactions and platelet declines. Ionis reported 8 serious adverse events concerned with volanesorsen.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.